Given a context passage, generate a question from the passage such that its answer is shortest continous span from the passage.

[EX Q]: Electronic book publishing has many of the same risks and opportunities as electronic music publishing. By delivering text direct to the user's computer screen, the e-book could cut down costs, and allow creators to deal directly with their audience, bypassing traditional publishers and readers. But it also raises the possibility of mass piracy . Phil Rance, founder and managing director of Online Originals, a London-based e-book publisher, sums it up. "No one wants Napster to happen to books." Indeed, the most popular MP3 have put the frighteners on an industry that generally operates some way behind the "bleeding edge". The Mata Group, a leading US-based market researcher, says publishers are far too concerned about protecting their rights, "We believe all the recent legal control over Napster is like putting a finger in a river that is already overflowing. Publishers need to deal with reality and come up with new ways to develop wide electronic distribution , asking the question: 'How can we use the certainty of wide distribution to our advantage?'" At the moment, most publishers would like to limit the use of e-books to the person who bought them, or to the computer used to download them. If that can be done, e-books become just an extra income stream in a publishing industry that would continue to operate the way it does today, according to Terry Robinson, business manager for Adobe's e-paper group. "If you've cracked digital rights aspect, you've cracked the market," he says. Robert Nichols, Books Director at BOL agrees, "Rights management is absolutely important. Publishers just say that 'until copyright is secure, we're not going to talk'."
[EX A]: What do publishers care most about e-books?

[EX Q]: 1. In order to investigate the biological function of the human CLN3 gene that is defective in Batten disease, we created a yeast strain by PCR-targeted disruption of the yeast gene (YHC3), which is a homologue of the human CLN3 gene. 2. The phenotypic characterization revealed that the yhc3 delta mutants are more sensitive to combined heat and alkaline stress than the wild-type strains as determined by inhibition of cell proliferation. 3. This suggests that the yhc3 delta mutant is a good model to investigate the biological function of human CLN3 gene in mammalian cells and to understand the pathophysiology of juvenile Batten disease.
[EX A]: What is the effect of a defective CLN3 gene?

[EX Q]: It has been reported that the R497K polymorphism of the epidermal growth factor receptor (EGFR) gene has attenuated functions in ligand binding, tyrosine kinase activation, and growth stimulation. On other hand, EGFR gene mutations at kinase domain in non-small cell lung cancer (NSCLC) have been examined for their ability to predict sensitivity to gefitinib or erlotinib. We investigated the EGFR mutations and/or R497K polymorphism statuses in 225 surgically treated NSCLC cases. 192 adenocarcinoma cases were included. The presence or absence of EGFR polymorphism of exon 13 was analyzed by PCR-RFLP method. EGFR mutations at kinase domain were found from 95 of 225 lung cancer patients. In 86.2% of patients, homo- or heterozygous Lys497 allele was present. No correlation existed between R497K EGFR genotype and clinico-pathological features, such as gender, smoking status, and pathological subtypes. EGFR mutation status was not correlated with R497KEGFR genotype of lung cancers. In node-negative patients, R497KEGFR genotype was not correlated with disease outcome. In node-positive patients, however, R497K EGFR was significantly associated with better overall survival. This association was attributable to neo-adjuvant or adjuvant chemotherapy. In 46 total gefitinib treated NSCLC patients, the prognosis was not different between the EGFR wild type (GG) patients and AG+AA patients. R497KEGFR polymorphism might be associated with favorable prognosis of advanced lung cancers and correlated with chemosensitivity.
[EX A]:
Mutations in which gene determine response to both erlotinib and gefitinib?